文献速递神经肿瘤

upfront伽玛刀放射外科治疗库欣病与肢端肥大症:一项多中心国际研究

Upfront Gamma Knife radiosurgery for Cushing's disease and acromegaly: a multicenter, international study.
PubMed 文献 · J Neurosurg · 2018-08-17

这项多中心国际研究汇总了7个伽玛刀中心46例(库欣病21例、肢端肥大症25例)接受 upfront 伽玛刀放射外科治疗的功能性垂体腺瘤患者的资料,中位内分泌随访69.5个月。全队列内分泌缓解率51%,肢端肥大症5年缓解率28%,库欣病5年缓解率81%,库欣病缓解更早(p=0.0005)。肿瘤稳定39%、缩小61%,垂体功能减退9例(19.6%),动眼神经麻痹1例(2.2%)。

要点

  • upfront 伽玛刀全队列内分泌缓解率51%,库欣病5年缓解率81%、肢端肥大症28%。
  • 库欣病较肢端肥大症缓解更早(p=0.0005)。
  • 肿瘤稳定39%、缩小61%;垂体功能减退19.6%,动眼神经麻痹2.2%。

核心结论

  • upfront 伽玛刀在整体队列中实现良好的肿瘤控制和较低的放射不良反应发生率。
  • 与肢端肥大症相比,库欣病患者接受 upfront 伽玛刀后缓解更快且缓解率远更高。
  • 对于不愿或无法接受切除术的经仔细选择的库欣病患者,可考虑将伽玛刀作为 upfront 治疗,但其在肢端肥大症中的作用较为有限。

研究设计与样本

  • 由7个伽玛刀中心参与的国际多中心研究,汇总46例接受 upfront 伽玛刀的功能性垂体腺瘤患者资料至协调中心分析。
  • 队列包括库欣病21例和肢端肥大症25例。
  • 诊断基于临床、内分泌和影像学研究确立。
  • 所有患者在同一放射外科平台治疗,并纵向随访肿瘤控制、内分泌缓解和垂体功能减退。
  • 肿瘤中位边缘剂量25 Gy(范围12–40.0 Gy),中位等剂量线50%。

主要发现

  • 中位内分泌随访69.5个月(范围9–246个月)。
  • 全队列内分泌缓解率51%,肢端肥大症5年缓解率28%,库欣病5年缓解率81%。
  • 库欣病较肢端肥大症更早实现缓解(p=0.0005)。
  • 伽玛刀后垂体腺瘤体积稳定者39%、缩小者61%。
  • 垂体功能减退9例(19.6%),动眼神经麻痹1例(2.2%);8例需进一步干预,其中重复伽玛刀6例、经蝶手术2例。

临床怎么用

  • 作者认为,对于不愿或无法接受切除术的经仔细选择的库欣病患者,可考虑将伽玛刀作为 upfront 治疗。
  • 作者认为,伽玛刀在肢端肥大症中的 upfront 作用较为有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gamma Knife radiosurgery (GKS) is typically used after failed resection in patients with Cushing's disease (CD) and acromegaly. Little is known about the upfront role of GKS for patients with CD and acromegaly. In this study, the authors examine the outcome of upfront GKS for patients with these functioning adenomas. METHODS: An international group of 7 Gamma Knife centers sent pooled data from 46 patients (21 with CD and 25 with acromegaly) undergoing upfront GKS to the coordinating center of the study for analysis. Diagnosis was established on the basis of clinical, endocrine, and radiological studies. All patients were treated on a common radiosurgical platform and longitudinally followed for tumor control, endocrine remission, and hypopituitarism. Patients received a tumor median margin dose of 25 Gy (range 12-40.0 Gy) at a median isodose of 50%. RESULTS: The median endocrine follow-up was 69.5 months (range 9-246 months). Endocrine remission was achieved in 51% of the entire cohort, with 28% remission in acromegaly and 81% remission for those with CD at the 5-year interval. Patients with CD achieved remission earlier as compared to those with acromegaly (p = 0.0005). In patients post-GKS, the pituitary adenoma remained stable (39%) or reduced (61%) in size. Hypopituitarism occurred in 9 patients (19.6%), and 1 (2.2%) developed third cranial nerve (CN III) palsy. Eight patients needed further intervention, including repeat GKS in 6 and transsphenoidal surgery in 2. CONCLUSIONS: Upfront GKS resulted in good tumor control as well as a low rate of adverse radiation effects in the whole group. Patients with CD achieved a faster and far better remission rate after upfront GKS in comparison to patients with acromegaly. GKS can be considered as an upfront treatment in carefully selected patients with CD who are unwilling or unable to undergo resection, but it has a more limited role in acromegaly.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Gupta A, Xu Z, Kano H, et al. Upfront Gamma Knife radiosurgery for Cushing's disease and acromegaly: a multicenter, international study. J Neurosurg. 2018. PMID: 30117768. doi:10.3171/2018.3.JNS18110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。